ProQR Therapeutics spent three years rebuilding after selling its failed eye-disease franchise, and the June healthy-volunteer readout on AX-0810 is the first time the replacement platform has moved a human biomarker. The Dutch clinical-stage company now asks the market to treat Axiomer, its ADAR-recruiting RNA editing method, as clinically real rather than a leftover science project. That ask arrives with a same-week equity raise that resets the share count and buys a cash clock into mid-2028. The investment debate is whether bile-acid target engagement in healthy adults is enough to re-rate a name still years from a patient outcome.
The print cleared management's own bar. Serum bile acids rose as much as eightfold at the six milligram dose, above the twofold threshold the company had set for meaningful NTCP modulation. Safety so far shows no serious events and no itch, and the estimated half-life of eight weeks supports infrequent dosing. Those are real pharmacology signals, not accounting noise. They are also still volunteer signals. Biliary atresia, the first intended patient setting, does not produce a clinical dataset until the China investigator-initiated study in the first half of 2027.
Cash finished the June quarter at €117 million, or about $136 million, after a registered-direct and Lilly private placement. Collaboration revenue more than doubled as deferred partner income converted, which is why the net loss narrowed even as research spend ticked higher. The market capitalizes the equity near $258 million, leaving an enterprise value that barely prices a year of platform optionality. Whether that discount is discipline or neglect turns on the full AX-0810 dataset later this year and on whether AX-0811, the more potent follow-on, actually reaches a first human cohort before year-end.